Mode
Text Size
Log in / Sign up
N/A Completed N=50

Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)

Source: ClinicalTrials.gov NCT00725010 ↗
Enrolled (actual)
50
Serious AEs
18.0%
Results posted
Nov 2010
Primary outcomePrimary: Safety: Number of Adverse Events in the Indicated Categories — 35; 1; 14; 0 Adverse Events

Summary

The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety: Number of Adverse Events in the Indicated Categories
35; 1; 14; 0; 22; 1 —
PRIMARY
Number of Participants Who Discontinued Due to Toxicity
8; 1 —

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed Glioblastoma multiforme

Exclusion Criteria

  • History of hypersensitivity to temozolomide or its components, or to dacarbazine.
  • Women who are pregnant or breast-feeding.
  • Patients with severe myelosuppression.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00725010). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search